
Alzamend Neuro (ALZN) Stock Forecast & Price Target
Alzamend Neuro (ALZN) Analyst Ratings
Bulls say
Alzamend Neuro Inc. has recently demonstrated promising progress in its clinical developments, notably with the positive top-line results from its studies announced in June 2023. The company's innovative pipeline, which includes two unique therapeutic candidates targeting neurodegenerative diseases, positions it favorably within the biopharmaceutical sector. Additionally, the current attractive valuation suggests significant potential upside, underscoring the potential for achieving key milestones to act as catalysts for future stock performance.
Bears say
Alzamend Neuro Inc reported a net loss of $2.7 million for the period, translating to an earnings per share (EPS) of $(1.28), which was significantly worse than the previous estimates of $(0.69). The company faces considerable risks that could undermine its share price, including challenges related to balance sheet liquidity, the efficacy and safety of its product candidates in clinical trials, and the regulatory approvals required for commercialization. Additionally, external factors such as competition in the biopharmaceutical sector, macroeconomic conditions, and shifts in healthcare priorities may further complicate the company's ability to achieve financial success.
This aggregate rating is based on analysts' research of Alzamend Neuro and is not a guaranteed prediction by Public.com or investment advice.
Alzamend Neuro (ALZN) Analyst Forecast & Price Prediction
Start investing in Alzamend Neuro (ALZN)
Order type
Buy in
Order amount
Est. shares
0 shares